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E-mail: roman.jerala@ki.siInﬂammation, which is a highly regulated host response
against danger signals, may be harmful if it is excessive and
deregulated. Ideally, anti-inﬂammatory therapy should auton-
omously commence as soon as possible after the onset of
inﬂammation, should be controllable by a physician, and
should not systemically block beneﬁcial immune response in
the long term. We describe a genetically encoded anti-inﬂam-
matory mammalian cell device based on a modular engineered
genetic circuit comprising a sensor, an ampliﬁer, a “thresh-
older” to restrict activation of a positive-feedback loop, a
combination of advanced clinically used biopharmaceutical
proteins, and orthogonal regulatory elements that linked
modules into the functional device. This genetic circuit was
autonomously activated by inﬂammatory signals, including
endogenous cecal ligation and puncture (CLP)-induced inﬂam-
mation in mice and serum from a systemic juvenile idiopathic
arthritis (sIJA) patient, and could be reset externally by a chem-
ical signal. The microencapsulated anti-inﬂammatory device
signiﬁcantly reduced the pathology in dextran sodium sulfate
(DSS)-induced acute murine colitis, demonstrating a synthetic
immunological approach for autonomous anti-inﬂammatory
therapy.
INTRODUCTION
Inﬂammation is a complex widespread response of multi-cellular
organisms that is activated by the innate immune system upon detec-
tion of danger signals emanating from pathogenic microorganisms
or from a damaged tissue.1 Inﬂammation is generally beneﬁcial for
the organism because it alerts the immune system to eliminate the
underlying cause and to restore homeostasis. However, deregulated
and excessive inﬂammation is harmful and may become chronic
due to positive feedback mediated by inﬂammatory cytokines. The
immune response is one of the most complex biological subsystems
with regulation involving various receptors, mediators, complex
feedback mechanisms, and different effector molecules, which
orchestrate the appropriate ﬁne-tuning of the response to danger.2,3
The rapid production of pro-inﬂammatory cytokines, such as tumor
necrosis factor alpha (TNF-a), interleukin 1 beta (IL-1b), IL-6, and
several others, is characteristic of autoimmune diseases, including in-
ﬂammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic
juvenile idiopathic arthritis (sJIA), multiple sclerosis, psoriasis, and102 Molecular Therapy Vol. 25 No 1 January 2017 ª 2017 The Americanlupus erythematosus, as well as of autoinﬂammatory diseases, such
as cryopyrin-associated periodic syndrome.4 The prevalence of in-
ﬂammatory diseases associated with excessive and harmful inﬂam-
mation is 5%–7%, even in societies with an advanced health care
system.5
Non-steroidal anti-inﬂammatory drugs (NSAIDs) and corticoste-
roids are widely used and effective anti-inﬂammatory therapies,
yet they can have adverse side effects. Currently, the most
advanced clinically used therapies for inﬂammatory diseases are
neutralizers of TNF-a (adalimumab, etanercept, and inﬂiximab)
and endogenous cytokine antagonists, such as anakinra (an IL-1b
antagonist) that speciﬁcally and effectively inhibit the activity of
pro-inﬂammatory cytokines.4 As inﬂammation is an essential
component of the host defense system, long-term systemic sup-
pression can cause adverse side effects, such as a decreased host
immune response against infections and an increased risk of cancer
development.4 Anti-inﬂammatory therapy that could match the
responsiveness and tunability of the natural cellular response, but
could be controlled externally, represents both a challenge and
an opportunity for synthetic biology. The strategy according to
the principles of synthetic biology is to construct biological systems
that are orthogonal to the existing signaling components yet are
able to read the inputs from the cellular processes or external sig-
nals and produce the physiologically relevant outputs. The
modular construction of interacting components allows this type
of systems to be adapted to the selected applications. Progress
has already been made in this direction, such as engineering of
the bacterium Lactococcus lactis to secrete IL-106 or anti-TNF-a
nanobody,7 which has been used in situ to locally treat murine
colitis. Escherichia coli that autonomously detect gut inﬂammation
through nitric oxide sensing has been reported,8 suggesting
the feasibility of more sophisticated inﬂammation management
strategies.Society of Gene and Cell Therapy.
Figure 1. Schematic Design of the Synthetic Anti-inflammatory Device
The anti-inflammatory device comprises three basicmodules (a sensor, an amplifier,
and an effector), which are connected through the transcriptional activator Gal4-
VP16 (GV16) and two supporting modules (an inducible OFF-switch and a
thresholder). The latter allows additional control of the system performance.
www.moleculartherapy.orgRecently, synthetic biologists have demonstrated several innovative
therapeutic strategies based on engineered mammalian cells designed
to respond to a physiologically relevant signal in a highly predictable
and controllable manner.9 Using microencapsulation technology,
such engineered cells could be implanted into a host.10,11 These cells
can act as prosthetic devices, which do not require any host genome
modiﬁcation. Of particular interest are sensor-effector designs that
can autonomously detect and treat various pathological conditions,
such as a malfunction in urate homeostasis,12 diet-induced obesity,13
and diabetic ketoacidosis.14 Recently, an innovative designer cell de-
vice to treat experimental psoriasis by converting the disease-relevant
inputs into the therapeutic output was presented.15
The therapeutic challenge in therapy of inﬂammatory diseases is to
detect and suppress inﬂammatory ﬂare-ups as soon as possible before
they are ampliﬁed through positive-inﬂammatory-feedback loops
and cause damage. Early intervention could clearly contribute to
beneﬁcial clinical outcomes in Crohn’s disease16,17 or sIJA.18 As a
safety and regulatory feature, implantable therapeutic cellular device
aimed at treating inﬂammation should be amenable to external con-
trol and capability to rest into the standby state once the inﬂamma-
tion has been resolved. Additionally, autonomous activation of the
device could also serve as a sensor of inﬂammation, reporting the pre-
vious inﬂammatory episode.
The inﬂammatory response is coordinated by highly complex regula-
tory networks, which consist of multiple, to some degree redundant
inducers, sensors, mediators, and effectors.1 In this study, we con-
structed a gene regulatory network that captured the required func-
tionalities of a ﬁne-tuned therapeutic device aimed to provide support
to the organism to cope with the dysregulated inﬂammatory response.
The introduced regulatory elements comprise several interactingfunctional modules that form a functional genetic circuit, which
can be integrated into and modulate the existing inﬂammatory
response. The prototypic synthetic anti-inﬂammatory device autono-
mously detected inﬂammatory signals at physiologically relevant
concentrations and responded by sustainable production of a combi-
nation of clinically used anti-inﬂammatory proteins that suppressed
inﬂammation, namely an anti-hTNF-a antibody in combination
with IL-10 or interleukin-1 receptor antagonist (IL-1RA). The anti-
inﬂammatory device was activated upon encounter of inﬂammatory
signals, including endogenous mouse inﬂammation induced by cecal
ligation and puncture (CLP) as well as by a serum sample from sJIA
patient, and reset by an external chemical inducer. The genetic device,
implemented by implantation of alginate-poly-L-lysine-alginate
(alginate-PLL-alginate) microencapsulated engineered cells into the
peritoneal cavity of mice, reduced the pathological symptoms in
dextran sodium sulfate (DSS)-induced acute murine colitis, demon-
strating a novel route of designed immunological intervention.
RESULTS
Design of the Functional Modules of the Synthetic
Anti-inflammatory Gene Circuit
To design an efﬁcient therapeutic anti-inﬂammatory device, we
aimed to combine the following characteristics: (1) real-time moni-
toring of physiologically relevant markers of inﬂammation; (2) an
ability to switch to a therapeutically active (ON) state in response
to physiologically relevant concentrations of an inﬂammatory
marker; (3) efﬁcient suppression of inﬂammation via sustained pro-
duction of anti-inﬂammatory effectors triggered by the activation of
the device; (4) control mechanism for preventing pre-mature inacti-
vation of the device by the neutralization of inﬂammation markers by
effectors in the immediate vicinity of the therapeutic cells; (5) and an
ability to reset the device to the standby state by external signal
(e.g., small-molecule inducer) that could potentially also be used in
clinical applications applied by a physician.
To detect and respond to an inﬂammatory signal, we developed a
biomolecular circuit, which comprises three basic modules: a sensor,
an ampliﬁer, and an effector (Figure 1). Thesemodules were intercon-
nected via the well-characterized transcriptional activator Gal4-VP16
(GV16),19 which is orthogonal to mammalian intracellular signaling
and transcriptional pathways. To demonstrate the concept of an anti-
inﬂammatory device that could be used in patients with inﬂammatory
diseases, we aimed to develop a system that could sense a common
signal of inﬂammation. As a large fraction of signals from the
danger-sensing receptors of the innate and adaptive immune system
converge on the activation of the NF-kB transcription factor,20 the
NF-kB-responsive sensor was chosen to monitor the inﬂammatory
status of tissue as reported by cellular receptors. To build and validate
the sensor, two different NF-kB-responsive elements were ﬁrst
examined. We utilized a validated combination of the kB DNA ele-
ments,21 which are speciﬁcally recognized by the NF-kB transcription
factor, and used the luciferase reporter activity as a readout. Con-
structs pAS36 (PNFkB1-PTAL-Luc, Table S1) and pAS37 (PNF-kB2-
PTAL-Luc, Table S1) driving the respective PNF-kB-PTAL luciferaseMolecular Therapy Vol. 25 No 1 January 2017 103
Figure 2. Characterization of the Functional Modules of the Synthetic Anti-inflammatory Gene Circuit
(A) Validation of the sensor construct (pAS48; PNF-kB2-PMIN-GV16) in HEK293T cells. Left: Dual luciferase test. Middle: confocal fluorescence microscopy (mCherry rep-
resents a seeding/transfection control). Right: model simulation of the stimulated and non-stimulated sensor-reporter pairs with increasing sensor amounts 24 hr after
stimulation. (B) Validation of the amplifier construct (pAS53; UAS-PMIN-GV16) in HEK293T cells. Left: Dual luciferase test. Middle: confocal fluorescence microscopy
(mCherry represents a seeding/transfection control). The amplifier autoactivates at higher amounts of transfected construct (cGV16 conditions and a confocal fluorescence
image). Additionally, it amplifies an effect of constitutively expressed GV16 as observed in cGV16+ conditions and from FI calculated from the relative light units (RLU) for each
amount of the transfected amplifier according the formula [cGV16+A+/cGV16+A], where A represents constitutive expression of GV16 from the pSGVP in the absence of
the amplifier (A(0ng) in the RLU graph). Right: model simulation of the amplifier-reporter pairs with increasing amplifier amounts after 24 hr. The effect of cGV16 was examined
by setting the particle number of GV16 at t = 0 to 1  106 for the cGV16+ simulation. (C) Functional circuit, composed of all the basic elements, except for the thresholder,
(legend continued on next page)
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www.moleculartherapy.orgexpression were introduced into human embryonic kidney 293 T
(HEK293T) cells, and construct pAS37 was selected as the sensor
design that produced the highest fold induction (FI) upon stimulation
with IL-1b or TNF-a (Figure S1A). The ectopic expression of the re-
ceptors for IL-1b and TNF-a was not required for the activation in
HEK293T cells (Figure S1A), indicating that the endogenous levels
were sufﬁcient, similarly as observed in other studies in HEK293
cells.22 Next, to decrease transcriptional leakage in the absence of
stimulation, the PTAL minimal promoter (derived from the pISRE-
Luc vector; Clontech) was replaced with the PMIN minimal promoter
(derived from the pGL4.23[luc2/minP]; Promega) to build a pAS40
construct, which enabled PNF-kB2-PMIN-driven expression of lucif-
erase (PNF-kB2-PMIN-Luc, Table S1). Apart from decreasing transcrip-
tional leakage, this modiﬁcation also increased the activation
amplitude, which increased the FI in response to IL-1b stimulation
from 25 to 150 (Figure S1B). Furthermore, the luciferase reporter
gene from the pAS40 vector was replaced by a GV16 transcriptional
activator to build pAS48 construct (PNF-kB2-PMIN-GV16, Table S1)
with an aim of testing whether GV16 could act as a module-connect-
ing mediator. IL-1b stimulation of the HEK293T cells transfected
with pAS48 resulted in the activation of the co-transfected reporter
plasmid pAS49 (UAS-PMIN-Luc, Table S1) that comprised ﬁve
consecutive Gal4 binding sites (upstream activating sequence
[UAS]), which enabled UAS-PMIN-driven luciferase expression (Fig-
ure 2A, left). To guide the experimental work by predicting the
responsiveness of the device to stimuli and to determine the optimal
transfection amounts, a deterministic model based on the ordinary
differential equations (ODEs) was constructed using CellDesigner
4.4 software.23 The mathematical model that used the parameters
derived from the experimentally determined values is represented
by a constructed state transition diagram of the genetic circuit (Fig-
ure S2) and is explained in detail in Supplemental Materials and
Methods. As predicted by the model (Figure 2A, right), in both stim-
ulated and non-stimulated settings, the response increased with the
increased amount of the transfected sensor. To visualize the activation
of the sensor construct in the cells in situ, the mCitrine reporter gene
was cloned in-frame with GV16 via the 2A peptide to build the
construct pAS97 (TRE-PNF-kB2-PMIN-GV16-myc-2A-mCit, Table
S1), which was monitored by confocal ﬂuorescence microscopy. Acti-
vation was observed only in the IL-1b-stimulated cells transfected
with the respective construct (Figure 2A, middle). Therefore, the
sensor construct enabled us to repurpose the endogenous inﬂamma-
tion-characteristic NF-kB signaling for the activation of the anti-
inﬂammatory device.
Once the activation of the device was optimized, we then aimed to
achieve sustained high-level production of anti-inﬂammatory pro-
teins. This production should be persistent even after the input signal
from the sensor, delivered by the inﬂammatory cytokines in the closetested in HEK293T cells. Left: dual luciferase test, reporter pAS51; TRE-UAS-PMIN-Luc
level of the device activation in stimulated and non-stimulated setting with increasing sen
increased from 0 to 10 ng, in 0.1-ng increments. Fold induction was calculated by div
effector particle number of non-stimulated circuit after 24 hr for each simulation. S, senproximity of the sensing cells, had decreased. The sustainability is
important to prevent pre-mature shutdown of the production of
anti-inﬂammatory therapeutics that neutralize the inﬂammatory
cytokines (i.e., the input signal) in the immediate vicinity of the
device. The sustainability of the system activation was achieved by
incorporation of the positive-feedback ampliﬁer module involving
the transcriptional activator GV16, which activates its own transcrip-
tion by binding to the UAS located upstream of the PMIN (Figure 1).
The mathematical model predicted that the ampliﬁer switches to an
activated state once a certain level of GV16 has been achieved due
to the positive-feedback loop (Figure 2B, right). To test the function-
ality of the ampliﬁer construct, HEK293T cells were transfected with
increasing amounts of the pAS53 construct (UAS-PMIN-GV16, Table
S1). Based on the mathematical model predictions, we reasoned that,
when the leakage surpasses the certain level, auto-activation would be
observed. Bymonitoring pAS49 reporter activity, this turned out to be
in the interval between 1 and 10 ng of pAS53 per well, which is in
accordance with the mathematical model. We have also demon-
strated that the ampliﬁer augmented the low-level signal of the consti-
tutively expressed GV16 (plasmid pSGVP) up to 4-fold in the relevant
range where the ampliﬁer itself was not yet auto-active (Figure 2B,
left). The auto-activation of the ampliﬁer-2A-tagBFP construct was
also observed directly by confocal ﬂuorescence microscopy (pAS98;
TRE-UAS-PMIN-GV16-myc-2A-tagBFP, Table S1) (Figure 2B, mid-
dle). Notably, the 2A fusion of mCitrine or tagBFP did not affect
the activity of the respective constructs (Figure S1C). Therefore, by
including a positive-feedback ampliﬁer module, our device gained
the ability to sustain high-level synthesis of therapeutic anti-inﬂam-
matory proteins.
To enable the external control over the activity of the device, an
inducible OFF-switch, implemented as the rtTR-KRAB repressor,24
was introduced. This switch reset the device by external chemical
signal and shut down production of the anti-inﬂammatory effectors
when they were no longer required. The orthogonal repressor binds
to the Tet-binding sites (Tet-responsive element [TRE]) and silences
gene expression only in the presence of doxycycline (Dox). The
repression effect of KRAB domain spreads several kilobases upstream
and downstream of its binding site.25 Thus, we positioned the TRE
into all three modules upstream of the other regulatory elements
to avoid disrupting the existing transcriptional architecture, which
could potentially impair the function of the ﬁne-tuned constructs.
The constitutively expressed rtTR-KRAB (pAS58; PCMV-rtTR-NLS-
KRAB, Table S1) repressed the reporter construct pAS51 carrying
the TRE-UAS-PMIN-driven luciferase expression unit (TRE-UAS-
PMIN-Luc, Table S1), which was activated by the GV16 (plasmid
pSGVP19). Efﬁcient and dose-dependent repression was achieved,
whereas in the absence of external reset signal the rtTR-KRAB
(pAS58) alone did not signiﬁcantly inﬂuence the system activation. Right: model simulation and parameter scan. The graph and heat maps depict the
sor and amplifier amounts after 24 hr. The amount of each respective construct was
iding the effector particle number after 24 hr of stimulation with the corresponding
sor; A, amplifier; FI, fold induction. Error bars indicate SD (n = 4).
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Molecular Therapy(Figure S1D, left). Similarly, we reset both the activated sensor and the
ampliﬁer circuit (Figure S1D, middle and right), suggesting a success-
ful implementation of the inducible OFF-switch function.
After testing and optimizing all the modules, they were incorporated
into a functional device. Based on the mathematical model of the
genetic network, we predicted higher leakage of the system at the
increased amounts of the transfected sensor and ampliﬁer constructs
(Figure 2C, middle and right). Based on those predictions, the ratio of
the sensor construct pAS60 (TRE-PNF-kB2-PMIN-GV16-myc, Table
S1) encoding TRE-PNF-kB2-PMIN-driven expression of GV16-myc
and the ampliﬁer construct pAS62 (pAS62; TRE-UAS-PMIN-GV16-
myc, Table S1) encoding TRE-UAS-PMIN-driven GV16-myc expres-
sion together with the inducible OFF-switch pAS58 and reporter
pAS51 was ﬁne-tuned (Figure 2C, left). The lowest amounts of the
sensor and the ampliﬁer constructs were used in all further experi-
ments. As a result, we observed a robust system induction triggered
by IL-1b, which was efﬁciently repressed by the addition of Dox (Fig-
ure 2C, left).
Introduction of the “Thresholder” and Sustained System Activity
by the Amplifier
It is important to restrict activation of the positive-feedback loop until
the signal is sufﬁciently strong. To decrease the transcriptional leakage
of the system and increase the FI, a thresholder module was intro-
duced. The thresholder concept is based on competition between
GV16 and the constitutively expressed Gal4 that lacks the VP16 acti-
vation domain, implemented as the construct pAS67 (PHSV-TK-G-
myc, Table S1; schematic representation in Figure 1), for binding to
the UAS operator in the ampliﬁer and effector constructs, which
acts as a threshold for the system activation. Usingmodel simulations,
we predicted that the constitutively expressed thresholder, which pro-
vides the constant amount of theUAS binding domain, should prevent
activation of the system until the signal from the sensor surpasses the
selected level, deﬁned by the amount of the expressed thresholder (Fig-
ure 3A, upper right and bottom). According to themodel simulations,
the thresholder decreased the unwanted background activity while re-
taining high ampliﬁcation (Figure 3A, upper right). Themathematical
simulations represented by the heat maps demonstrated the effect of
increasing thresholder amounts on the level of the device activation
with rising leaky transcription rates (kl) (Figure 3A, bottom). Experi-
mental testing of the thresholder demonstrated its function in agree-
ment with the simulations, decreasing leaky transcription and
consequently increasing the FI (Figure 3A, upper left and middle).
Importantly, the activated state remained high even at thresholder
amounts that strongly decreased the leakage of the unstimulated state.
This made it possible to tune the thresholder amount that gave the
highest FI of approximately 60 (Figure 3A, upper left and middle).
To our knowledge, this is a novel approach for decreasing transcrip-
tional leakage in mammalian cells, which could be applicable to other
systems employing positive-feedback regulation.
Furthermore, we tested additional characteristics of the ﬁnal circuit
when both the ampliﬁer and the thresholder constructs were present.106 Molecular Therapy Vol. 25 No 1 January 2017To evaluate the contribution of the ampliﬁer to the amplitude and ki-
netics of the response, the systemwas stimulated for 24 hr (or 4 hr, Fig-
ure S3A). The medium was then replaced to remove the inducer. The
ampliﬁer sustained the response, which remained increased as much
as 5-fold after 72 hr, compared to the decreased response of the system
without the ampliﬁer (Figure 3B). Thus, the ampliﬁer enabled sus-
tained system activation, which is important to avoid pre-mature
decrease of anti-inﬂammatory therapeutics production. Importantly,
at the same time, the ﬁne-tuned strength of the positive-feedback
loop enabled us to retain concentration-dependent system activation
supported by the sensor construct (shown later in the text).
Additionally, the response of the pAS97 and pAS98 constructs in the
ﬁnal device was monitored directly. As shown in Figure S3B, they
were both activated only when an input signal was present, and
they remained silent if Dox was also added. The ampliﬁer construct
should, in principle, switch to an ON state only after the sensor has
been activated and the threshold level of Gal4 has been outcompeted
by GV16 induced by the sensor. Thus, we veriﬁed whether the acti-
vated sensor and ampliﬁer constructs were present in the same cell.
This was demonstrated by colocalization of the ﬂuorescently tagged
activated sensor and ampliﬁer (Figure S3C).
After the successful construction of the system, its activation capacity
was investigated. Low amounts (Table S2) of transfected sensor and
ampliﬁer constructs in the ﬁne-tuned system yielded a comparable
output from the reporter pAS51 as triggered by the equal amount
of the constitutive CMV-driven reporter (Figure S1C).
Activation of the Anti-Inflammatory Device Ex Vivo and In Vivo
Next, we investigated the responsiveness of the anti-inﬂammatory de-
vice to physiologically relevant inﬂammatory signals. As described in
the previous sections, we ﬁne-tuned the strength of the positive-feed-
back loop to retain concentration-dependent system activation. First,
we stimulated the engineered cells with increasing amounts of IL-1b
and TNF-a, and observed a gradual increase in activation (Figure 4A).
Inﬂammatory cytokine (IL-1b, TNF-a, and IL-6) levels in healthy
humans range between undetectable amounts to approximately
10 pg/mL,26,27 whereas they are strongly elevated in patients with
active inﬂammatory disease. For example, in RA patients, levels of
as much as 109 pg/mL of TNF-a and 184 pg/mL of IL-6 were de-
tected.28 Because IL-1b has a short half-live in vivo,29,30 its secretion
is often investigated indirectly by stimulating cultured peripheral
blood mononuclear cells (PBMCs). It was shown that serum from
sIJA patients induced secretion of an approximately 100 pg/mL of
IL-1b in healthy PBMCs.31 As our aim was to design a system that
could, in principle, function in humans, it was important that the
anti-inﬂammatory device-engineered cells responded at physiologi-
cally relevant concentrations. Notably, the system was far less respon-
sive to mouse cytokines, as human receptors are not activated by
mouse cytokines as potently as by human cytokines (Figure 4A).
We further demonstrated the physiological relevance of the anti-
inﬂammatory device by demonstrating that the serum of healthy
Figure 3. Introduction of the Thresholder and the Effect of the Amplifier
(A) Left: transcriptional leakage of the system was efficiently reduced by a thresholder (pAS67; PHSV-TK-G-myc) tested in HEK293T cells. Right: model simulation and
parameter scan. The graph depicts the level of the device activation in stimulated and non-stimulated setting with the increasing thresholder. Bottom panels: heat maps
represent the effect of increasing thresholder amounts on the level of the device activation with rising leaky transcription rates (kl) after 24 hr. (B) Anti-inflammatory device-
engineered HEK293T cells (reporter pAS72; TRE-UAS-PMIN-SEAP) were stimulated with hIL-1b for 24 hr, and then the input signal was removed by exchanging the medium.
SEAP production was quantified in the culture supernatants every 24 hr along with a medium exchange to observe the kinetics of the system activation. S, sensor;
A, amplifier; R, reporter; FI, fold induction. Error bars indicate SD (n = 4).
www.moleculartherapy.orghuman individuals did not activate the anti-inﬂammatory device,
whereas the 1:1-diluted human serum from a sIJA patient activated
the system approximately 3.5-fold (Figure 4B).
We alsoobserved high ex vivo systemactivationusingperitoneal lavage
ﬂuid collected 1hr after an injection of human IL-1b andTNF-a (intra-
peritoneally [i.p.]) in mice (Figure 4C). The activation, however,
strongly decreased when using peritoneal lavage ﬂuid collected 6 hr
after the injection and was undetectable when stimulating with the
one, collected after 24 hr (Figure 4C), that highlights the short half-
life of the injected cytokines (Figure S4A). To demonstrate activation
of the anti-inﬂammatory device by endogenous inﬂammation in
mice, CLP procedure, which is frequently utilized as an animal model
of sepsis and is characterized by high level of inﬂammatory cytokines(Figure S4B), was performed.32 Peritoneal lavage ﬂuid collected 24 hr
after the CLP procedure demonstrated ex vivo activation of the de-
signed device transfected in HEK293T cells (Figure 4D).
To test the functionality of the implemented anti-inﬂammatory de-
vice in vivo, the engineered cells were microencapsulated in algi-
nate-PLL-alginate beads and were implanted into the peritoneal
cavity of mice. An intracellular luciferase reporter, present in the
pAS51, was replaced by a secretory alkaline phosphatase (SEAP) to
construct the pAS72 reporter plasmid (TRE-UAS-PMIN-SEAP, Table
S1). A signiﬁcant increase in serum SEAP levels was observed 48 hr
after i.p. injection of human IL-1b or TNF-a, whereas the device
remained silent in the absence of cytokines (Figure 4E). A similar in-
crease in the SEAP activity was detected in the serum after 24 hr andMolecular Therapy Vol. 25 No 1 January 2017 107
Figure 4. Activation of the Anti-inflammatory
Device In Vitro and In Vivo
(A) The responsiveness of the system to recombinant
human and mouse interleukin-1b (IL-1b) and tumor
necrosis factor a (TNF-a) was tested in the anti-inflam-
matory device-engineered HEK293T cells by a dual
luciferase test (reporter pAS51; TRE-UAS-PMIN-Luc) after
a 24-hr activation period. Error bars indicate SD (n = 4).
(B) The responsiveness of the system to pooled healthy
human serum (n = 4) and the serum of a patient with
systemic juvenile idiopathic arthritis (sJIA). Error bars
indicate SD (n = 4). (C) Activation of the anti-inflammatory
device-engineered HEK293T cells ex vivo by a peritoneal
lavage fluid of mice, injected i.p. with hIL-1b (300 ng/mice)
or hTNF-a (250 ng/mice). The peritoneal lavage fluid was
collected at different time points. Error bars indicate SD
(n = 4). (D) Activation of the anti-inflammatory device-
engineered HEK293T cells ex vivo by endogenousmouse
cytokines in a peritoneal lavage fluid of mice that were
subjected to the cecal ligation and puncture (CLP). The
peritoneal lavage fluid was collected 24 hr after CLP
procedure. Error bars indicate SD (n = 4). (E) The
responsiveness of the system in vivo. The anti-
inflammatory device-engineered HEK293T cells (reporter
pAS72; TRE-UAS-PMIN-SEAP) were microencapsulated
and implanted i.p. An inflammatory signal was induced
i.p. with an injection of hIL-1b (300 ng/mouse) or hTNF-a
(250 ng/mouse) 1 and 24 hr post-implantation. Serum
SEAP levels were profiled after 48 hr. Error bars indicate
SD (n = 5). (F) The responsiveness of the implanted
anti-inflammatory device to endogenous CLP-induced
inflammation in mice. CLP procedure was performed
24 hr beforemicrocapsules implantation, and SEAP levels
were measured 48 hr post-implantation. Y, mass
concentration; FI, fold induction; Ctrl. m., control
microcapsules; Control, control mice. Error bars indicate
SD (n = 5).
Molecular Therapyin the peritoneal lavage ﬂuid after 48 hr (Figure S4C). The trend of
in vivo studies was similar to that observed in parallel in vitro exper-
iments (Figure S4D, left). As an internal control of the system, a
construct for a secretory Renilla luciferase under the constitutive pro-
moter, SR-Luc (pAS75; PCMV-SR-Luc, Table S1), was designed and
co-transfected along with the anti-inﬂammatory device. As seen in
Figure S4D, right, the SR-Luc was comparable among the groups,
indicating similar amounts of implanted microcapsules and similar
microencapsulated cell viability. In a similar vein to ex vivo experi-
ments, we have also demonstrated that the CLP procedure in mice108 Molecular Therapy Vol. 25 No 1 January 2017resulted in elevated inﬂammatory cytokines,
measured in the peritoneal lavage ﬂuid and
serum (Figure S4B), and led to an autonomous
activation of the implanted anti-inﬂammatory
device by the endogenous inﬂammation in vivo
(Figure 4F).
These results therefore demonstrated that the
microencapsulated anti-inﬂammatory devicewas able to respond reliably to an inﬂammatory signal in a complex
biological environment when implanted into the peritoneal cavity
of mice.
Design and Biological Activity of the Composite Anti-
Inflammatory Therapeutic Proteins
Upon activation, a functional anti-inﬂammatory device should
produce a therapeutically relevant output. For this purpose, we
designed an advanced effector construct based on clinically used
anti-inﬂammatory biopharmaceuticals, anti-human TNF-a antibody
(legend on next page)
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receptor antagonist (hIL-1RA), and mouse interleukin 10 (mIL-10).
To produce a stoichiometric amount of the heavy and light antibody
chain, the effector construct was designed as a single mRNA tran-
script comprising coding sequences for three polypeptide chains, an
anti-hTNF-a antibody heavy chain, an anti-hTNF-a antibody light
chain, and hIL-1RA or mIL-10. The polypeptide-coding chains
were linked through the coding sequence for the 2A peptide, which
interrupts the translation of the polypeptide chain, similar as
described previously34 (Figure 5A). These composite anti-inﬂamma-
tory therapeutics were integrated in the ﬁnal effector constructs
pAS116 (TRE-UAS-PMIN-anti-hTNF-a Ab-hIL-1RA) and pAS134
(TRE-UAS-PMIN-anti-hTNF-a Ab-mIL-10, Table S1). The constitu-
tive and inducible production of the anti-hTNF-a antibody and
hIL-1RA separately, or coupled in the ﬁnal effector construct, was
validated by western blot analysis (Figure S5A). The ability and
efﬁciency of the antibody molecules to traverse the membrane of
the microcapsules was demonstrated (Figures S5B–S5D). Production
of hIL-1RA, anti-hTNF-a, and mIL-10 from the pAS116 or pAS134-
transfected microencapsulated cells was quantiﬁed by an ELISA.
We determined the production of hIL-1RA, anti-hTNF-a antibody,
and mIL-10 in the stimulated system (Figure 5B; see Figure S5E for
SR-Luc). The unstimulated and the stimulated and subsequently
Dox-reset system did not produce substantial amounts of anti-in-
ﬂammatory effectors (Figure 5B; see Figure S5E for SR-Luc). Similar
results were obtained in vitro with an inducible anti-hTNF-a
(pAS113; TRE-UAS-PMIN-anti-hTNF-a Ab, Table S1), mIL-10 in
the setting with or without the effector construct pAS134, and
constitutive hIL-1RA (pAS35; Pcmv-hIL-1RA-myc, Table S1) alone
(Figure S5F).
The in vivo production of the effectors from the microencapsulated
engineered cells implanted into the peritoneal cavity of mice was
demonstrated. We detected 1 ng/mL of hIL-1RA and 150 ng/mL of
anti-hTNF-a in the serum or 7 ng/mL of hIL-1RA and 30 ng/mL
of anti-hTNF-a in the peritoneal lavage ﬂuid 48 hr post-implantation
only when the mice with implanted device were stimulated with hu-
man IL-1b and TNF-a. Mouse IL-10 was detected in the peritoneal
lavage ﬂuid at 200 pg/mL 72 hr post-implantation (Figure 5C; see Fig-Figure 5. Design and Biological Activity of Composite Anti-inflammatory Thera
(A) Schematic representation of the double effector construct. The construct was desig
antibody heavy chain, anti-hTNF-a antibody light chain, andmouse IL-10 (mIL-10) or hum
for the 2A peptide. Each coding sequence contains its own signal peptide (SP) and an a
protein translation, self-processing, and furin and signal peptide cleavage, the mature
counteracted inflammation. (B and C) In vitro (B) and in vivo (C) expression of the anti-infl
inflammatory device-engineered HEK293T cells were microencapsulated, and 700 mL o
In vitro, the anti-inflammatory device was stimulated with a combination of interleukin-1
subsequently shut down by doxycycline (Dox) (1 mg/mL). For in vivo expression, the mice
mouse 1 hr after implantation. Serum and peritoneal lavage fluid were collected 48 or 7
and hIL-1RA concentrations were determined by an ELISA test. (D) The responsiveness o
in mice. CLP procedure was performed 3 hr before microcapsules implantation, and SE
1RA and the anti-hTNF-a antibody was determined in vitro by competitive inhibition of h
Luc). We stimulated cells with 20 ng/mL hIL-1b or hTNF-a for 24 hr, to which we adde
anti-inflammatory proteins. SN, supernatant; Ctrl. m., control microcapsules; M, with
110 Molecular Therapy Vol. 25 No 1 January 2017ure S5E for SR-Luc). Similar results were obtained for the constitutive
in vivo production of hIL-RA (Figure S5G). Similarly as described
above (Figure 4F), we have shown autonomous in vivo activation of
the device by the CLP procedure, detected by anti-inﬂammatory ther-
apeutics 72 hr post-implantation (Figure 5D). We speculate that the
different concentration and distribution of therapeutic proteins be-
tween serum and peritoneal lavage ﬂuid are due to the two factors.
First, a longer serum half-life of human IgG1 antibody (approxi-
mately 3 days35) enables wide distribution of anti-hTNF-a and its
accumulation in the serum, compared to the shorter-lived hIL-1RA
and mIL-10 (serum half-life of an approximately 30 min36,37 and
2 hr,38 respectively), which results in the highest concentration in
the vicinity of the implanted microcapsules. Second, the peritoneal
lavage ﬂuid-collecting procedure (see Materials and Methods) dilutes
the local concentration of therapeutic proteins. In this way, the con-
centration of more evenly distributed anti-hTNF-a is higher in the
serum than in the diluted peritoneal lavage ﬂuid, whereas the concen-
tration of hIL-1RA and mIL-10 is higher in peritoneal lavage ﬂuid
even after dilution, because their short circulating half-life compro-
mises their accumulation in the serum.
The biological activity of hIL-1RA and anti-hTNF-a, produced in
the HEK293T cells, was demonstrated in vitro by the inhibition of
hIL-1b or hTNF-a signaling, respectively. Approximately 3-fold
molar excess was required for 50% inhibition for both effectors,
which was similar to the recombinant proteins used as controls (Fig-
ure 5E). Altogether, in this set of experiments, we were able to
successfully construct and test composite anti-inﬂammatory thera-
peutic proteins.
Resetting of the Anti-Inflammatory Device In Vitro and In Vivo
Next, we demonstrated in vitro that, once activated, the device could
be reset to the resting state by the addition of Dox after 24 hr. Com-
plementary, when the device was initially reset by Dox, it could be
reactivated by an inﬂammatory signal (Figures 6A and S6A). Further-
more, we wanted to recapitulate these results in vivo. First, we stim-
ulated the implanted device for 1 hr to activate the circuit and then
injected Dox, which prevented full system activation, as measured
by SEAP release (Figure 6B; see Figure S6B for SR-Luc). Next, wepeutics
ned as a single mRNA transcript comprising coding sequences for the anti-hTNF-a
an interleukin-1 receptor antagonist (hIL-1RA), linked through the coding sequence
dditional furin cleavage site to truncate the length of 2A cleavage residues. After the
anti-inflammatory effectors were assembled, resulting in a mixture of proteins that
ammatory therapeutics from the effector constructs indicated in the figure. The anti-
f suspension was either incubated in vitro in 10 mL of media or implanted i.p. in mice.
b (IL-1b) (10 ng/mL) and tumor necrosis factor a (TNF-a) (10 ng/mL) or, in addition,
were injected i.p. with a combination of 500 ng of hIL-1b and 250 ng of hTNF-a per
2 hr post-implantation as indicated in the figure. The anti-hTNF-a antibody, mIL-10,
f the implanted anti-inflammatory device to endogenous CLP-induced inflammation
AP levels were measured 72 hr post-implantation. (E) The biological activity of hIL-
IL-1b and hTNF-a signaling via the NF-kB promoter (reporter pAS40; PNF-kB2-PMIN-
d (simultaneously or with 30-min preincubation) the titrated supernatant, containing
out microcapsules; M+, with microcapsules. Error bars indicate SD (n = 4).
Figure 6. Reversibility of the Synthetic Anti-inflammatory Device In Vitro and In Vivo
(A) Reversibility of the synthetic anti-inflammatory device in vitro. Left: shutdown of the system. The anti-inflammatory device-engineered HEK293T cells (reporter pAS72;
TRE-UAS-PMIN-SEAP) were stimulated with hIL-1b (1 ng/mL) for 24 hr and then shut down by the addition of the doxycycline (Dox) (1 mg/mL) by exchanging the medium
(indicated by the arrows). Right: rebooting of the initially shut down system. The anti-inflammatory device-engineered HEK293T cells (reporter pAS72; TRE-UAS-PMIN-SEAP)
were shut down by Dox (1 mg/mL) for 24 hr and then reactivated by the addition of hIL-1b (1 ng/ml) during medium exchange (indicated by the arrows). Error bars indicate SD
(n = 4). (B) In vivo restraint of the full system activation. The anti-inflammatory device-engineered HEK293T cells (reporter pAS72; TRE-UAS-PMIN-SEAP) were micro-
encapsulated and implanted i.p. One hour after implantation, the mice were injected i.p. with a combination of 300 ng of hIL-1b and 250 ng of hTNF-a per mouse. After 1 hr
and then every 24 hr, the device was shut down by an i.v. Dox injection (20mg/kg). Serumwas collected daily, and SEAP levels weremeasured. (C and D) In vivo shut down of
the system. The anti-inflammatory device-engineered HEK293T cells (effector pAS134; TRE-UAS-PMIN-anti-hTNF-a Ab-mIL-10) were microencapsulated, implanted i.p.,
and fully activated by injection of a combination of 300 ng of hIL-1b and 250 ng of hTNF-a per mouse. After 24 hr (thin arrow), the device was shut down by an i.v. Dox injection
(20 mg/kg). (C) The device was additionally activated and shut down after 72 hr (thick arrow) to reach the relevant time span needed for an observation of the anti-hTNF-a
antibody kinetics. Serum was collected at different time points, and (C) anti-hTNF-a antibody or (D) mIL-10 levels were measured. (E) Reactivation of the anti-inflammatory
device in vivo. The anti-inflammatory device-engineered HEK293T cells (effector pAS134; TRE-UAS-PMIN-anti-hTNF-a Ab-mIL-10) were microencapsulated and shut down
by i.v. Dox injection (20 mg/kg) 1 hr after implantation. After 72 hr, the system was activated by a single application of 300 ng of hIL-1b and 250 ng of hTNF-a per mouse.
Implanted anti-inflammatory device alone represented the control group. Anti-hTNF-a antibody concentration was profiled in the peritoneal lavage fluid 120 hr after
implantation. Error bars indicate SD (n = 4).
www.moleculartherapy.orgwanted to demonstrate in vivo reset of the fully activated system by
injecting Dox 24 hr after activation (thin arrow in Figure 6C)
and measuring the anti-inﬂammatory therapeutics concentrations
(pAS134; TRE-UAS-PMIN-anti-hTNF-a Ab-mIL-10, Table S1).
Considering a long half-life of human IgG1 antibody (approximately
3 days35) and likewise of the SEAP (approximately 1 day39) in vivo in
mice and taking in account the kinetics of the reset switch shown in
Figure 6A, there was no difference in the anti-hTNF-a antibody
serum concentrations 48 hr after Dox injection, because the fully acti-vated device secreted anti-hTNF-a antibody that accumulated in the
circulation during that period (Figure 6C). Therefore, the experiment
was prolonged and the device was additionally reset 72 hr after the
ﬁrst activation (thick arrow in Figure 6C). In this case, the device
was activated simultaneously with the reset. This was done to ensure
the full activity of the circuit receiving signals from the sensor and the
ampliﬁer constructs in the ON group throughout the time course of
the experiment and to show the ability to keep the system shut
down even in the presence of the inﬂammatory signal (i.e., theMolecular Therapy Vol. 25 No 1 January 2017 111
Molecular Therapydominant effect of the OFF-switch) in the OFF group. One hundred
twenty hours after the implantation, the activity of the initially fully
activated system dropped to around 20%, demonstrating an efﬁcient
reset in vivo (Figures 6C and S6C). Additionally, whenmIL-10, which
has a short serum half-life (approximately 2 hr38), was monitored, we
demonstrated that one injection of Dox 24 hr after the system activa-
tion (thin arrow in Figure 6D) decreased the activity of fully activated
system to around 20% after 48 hr (Figures 6D and S6D). Finally, we
have shown in vivo that, if the system was initially reset by Dox injec-
tion 1 hr after implantation, it could be reactivated by a single appli-
cation of human IL-1b and TNF-a 3 days after, as measured by the
presence of anti-hTNF-a antibody in the peritoneal lavage ﬂuid
120 hr after implantation (Figure 6E). However, the in vivo reactiva-
tion was low by means of capacity, presumably because of the tran-
sient nature of the system as shown in Figure S7A and possibly also
due to the residual Dox in the bloodstream (half-life of an approxi-
mately 3 hr in mice40).
Application of the Anti-inflammatory Device In Vivo in the Acute
Murine Colitis
The anti-inﬂammatory device was designed and optimized to func-
tion in humans. Here, we tested the robustness of the system and
the efﬁciency of the composite anti-inﬂammatory therapeutics also
in an animal disease model. We tested the in vivo physiological func-
tionality of the implanted device in the amelioration of acute (8-day)
DSS-induced murine colitis. Although we have shown activation of
the anti-inﬂammatory device by endogenous mouse cytokines in
the CLP model (Figures 4F and 5D), the DSS-induced murine colitis
did not result in the sufﬁcient increase of the endogenous systemic in-
ﬂammatory cytokines to activate the system, as substantial amounts
were detected only in the supernatants of colon biopsy samples (Fig-
ure S7B) and the receptors of human HEK293T cells are far more
responsive to the human than mouse inﬂammatory cytokines as
shown in Figure 4A. To mimic an inﬂammatory ﬂare and to reach
an optimal effect in a DSS-induced murine colitis, we stimulated
the microencapsulated anti-inﬂammatory device by injecting human
inﬂammatory cytokines. As a therapeutic output, a combination of
anti-hTNF-a, which also inhibits mTNF-a,33 and mIL-10 was used,
because both anti-inﬂammatory therapeutics have previously shown
efﬁciency in a mouse colitis model.6,7 When the microencapsulated
anti-inﬂammatory device was implanted on the ﬁfth day of the exper-
imental model (i.e., 5 days after the starting of the DSS exposure), a
signiﬁcantly reduced colon shortening was observed, when mice
were sacriﬁced on the eighth day, in comparison to the control
without microcapsules or the implants containing the engineered
cells without the effector module (Figure 7A). The microencapsulated
anti-inﬂammatory device clearly improved the intestinal morphology
as observed at the end of the in vivo experiment, compared to that of
the controls (Figure 7B), and signiﬁcantly reduced the daily moni-
tored disease activity index, deﬁned by the stool form and stool blood
(Figure 7C). Furthermore, the anti-inﬂammatory device improved
the colon histopathology (Figure 7E) and consequently the histolog-
ical score (Figure 7F), which was evaluated on the eighth day upon
sacriﬁce of the mice. Colon from animals with the implanted anti-112 Molecular Therapy Vol. 25 No 1 January 2017inﬂammatory device showed less inﬁltration of lymphocytes and
neutrophil granulocytes, less crypt damage, and no formation of
ulcers. In control animals, foci of hydropic degeneration were also
observed in contrast to mice with implanted active device. When
the anti-inﬂammatory device was implanted on the third day after
DSS exposure, activated, and simultaneously restrained by Dox, a sig-
niﬁcant difference in the amount of body mass lost was measured on
the ﬁfth day (2 days after the implantation of the device), compared to
the device that remained activated (Figure 7D). However, at later time
points, the device was not able to reverse the body mass loss, presum-
ably because of the severity of the damage to the gastrointestinal tract
caused by DSS and possibly also because of the decrease of the cir-
cuit’s therapeutic capacity at later time points due to the transient
nature of the system (Figure S7A).
DISCUSSION
Several innovative concepts for a variety of medical applications have
already been introduced employing the principles of synthetic
biology.41 One particularly promising strategy is the modiﬁcation of
mammalian cells by designed genetic therapeutic networks that
autonomously sense pathological conditions (i.e., metabolites or
other signature molecules) and respond by a therapeutic output.9
When implanted into the host organism, such engineered cells act
as therapeutic prosthetic devices. In this way, synthetic biology could
contribute to the next generation of cell-based therapies for important
medical problems, representing a new pillar of pharmacotherapy.42
Inﬂammatory processes are central to many widespread diseases
such as IBD, which alone affects more than 2 million people in
Europe.43 As pro-inﬂammatory cytokines are the key pathophysio-
logical components in the inﬂammatory disease manifestation,44 bio-
logical drugs that interfere with those mediators represent an effective
therapy.45
The anti-inﬂammatory device developed in this study enabled a
prompt detection of inﬂammatory signals requiring only 4 hr of
stimulation (Figure S3A) and the initiation of an in vivo localized
therapeutic response designed to be strengthened by the ampliﬁer
device. In addition to its inﬂammatory signal-induced rapid response,
a major advantage of the therapeutic device compared to established
biological therapies, such as TNF-a and other inﬂammatory cytokine
neutralizers, is the avoidance of long-term systemic blockage of
beneﬁcial inﬂammatory reactions. Upon future developments of
the therapeutic systems, the main medical conditions that might
beneﬁt from the anti-inﬂammatory device are chronic inﬂammatory
diseases or medical conditions with high risk of acute inﬂammatory
ﬂare-ups.
We demonstrated that the sensor module enabled dose-dependent
activation of the device at physiologically relevant concentrations of
inﬂammatory mediators both in vitro and in vivo in mice (Figures
4 and 5). Similarly as in other studies,13 the dynamic range of the ge-
netic circuit in the in vivo conditions did not fully recapitulate the
in vitro setting, but nevertheless we have demonstrated that the device
Figure 7. Anti-inflammatory Device Demonstrates
Efficacy by Reducing the Symptoms in the Acute
Murine Colitis
The anti-inflammatory device-engineered HEK293T cells
(double effector pAS134; TRE-UAS-PMIN-anti-hTNF-a
Ab-mIL-10) were microencapsulated and implanted i.p.
into mice with DSS-induced acute murine colitis on
the fifth day (except for D) of the experimental model
(i.e., 5 days after exposing mice to DSS). One hour after
implantation, the device was activated by a combined
inflammatory signal (an i.p. injection containing a combi-
nation of 300 ng of hIL-1b and 250 ng of hTNF-a per
mouse). (A) The anti-inflammatory device blocked colon
shortening induced by DSS (themean ± SD is shown) and
(B) improved the intestinal morphology as validated at the
end of the in vivo experiment; (C) reduced daily monitored
disease activity index, defined by the combined scores of
stool consistency and stool blood (two-tailed Student’s
t test assuming unequal variances; mean ± SEM is
shown); (D) temporarily reduced daily monitored body
mass loss (each data point represents the body
mass measurement of one mouse); and, as measured
upon the sacrifice of the mice, (E) improved colon histo-
pathology, and (F) the histological score (Mann-Whitney
U test; mean ± SEM is shown). Without m., without
microcapsules.
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SEAP as an output (Figures 4E and 4F). When therapeutic proteins
were proﬁled in the serum or peritoneal lavage ﬂuid of mice, a better
dynamic range was observed, which was attributed to the lower back-
ground (Figures 5C and 5D). Additionally, ex vivo activation by
human serum from a sIJA patient was demonstrated (Figure 4B).
sJIA is an auto-inﬂammatory disease affecting 250,000 children in
the United States alone.31 Anakinra has been previously shown to
have a beneﬁcial effect on the disease outcome, when administered
early in the disease progression before arthritis has become well estab-
lished.18 That is exactly what the described anti-inﬂammatory device
enables and anakinra as a therapeutic output was also validated in this
study (Figures 5B, 5C, and 5E). The activation of the system by the
human serum from sIJA patient was lower than in the in vitro titra-
tion experiment. This is in part due to the dilution of the serum usedMin this experiment, but also due to a very short
half-life of hIL-1b in the human serum.29,30
Considering these limitations, a 3.5-fold induc-
tion is probably an underestimation of what the
systems’ response would be in a hypothetical
in vivo setting, where the circulating hIL-1b
would fuel the activity of the implanted device.
Nevertheless, it remains to be investigated,
whether this level of activation would sufﬁce
for the therapeutic efﬁcacy in the in vivo setting,
which clearly depends on the particular inﬂam-
matory disease being targeted. Although the
anti-inﬂammatory device was optimized for ahuman setting, activation by endogenous mouse cytokines was shown
in the CLP model of sepsis in vivo (Figures 4F and 5D).
The notion and application of a threshold for regulation has already
been established in DNA nanotechnology, where in vitro DNA strand
displacement enabled a construction of neural networks by linear
threshold circuits.46 The novelty of our designed circuit is introduc-
tion of the thresholder, which decreases the transcriptional leakage
in themammalian cell system. This was achieved by a competition be-
tween transcriptionally active and inactive proteins for the sameDNA
binding site (Figure 3A). This principle contributes to the synthetic
biology toolbox for mammalian cell engineering and could be applied
in genetic circuits that are prone to a transcriptional leakage. It has
been demonstrated by others47,48 that repeated DNA sequences con-
taining transcription factor binding sites that are not coupled toolecular Therapy Vol. 25 No 1 January 2017 113
Molecular Therapysystem activation can act as decoys. In this way, by sequestering tran-
scriptional activator, decoy binding sites can inﬂuence the properties
of the circuit by increasing its ultra-sensitivity. On the other hand,
when designing complex gene circuits by joining several modules,
decoy DNA binding sites can apply a load to a system and negatively
inﬂuence circuit function, which was alleviated by a designed load
driver device.49 However in this study, we did not test how the thresh-
older affected ultra-sensitivity of the system, because our primary goal
was to decrease the transcriptional leakage of the circuit. Upon intro-
duction of the thresholder, our circuit retained graded response,
which depended on the concentration of the input inﬂammatory sig-
nals (Figure 4A).
The activated device produced sufﬁcient amounts of biologically
active anti-inﬂammatory therapeutic proteins in vitro (Figure 5B)
and in vivo (Figures 5C and 5D) to impair the excessive inﬂammation
and its pathological effects. Sustained production of effector proteins
was achieved by incorporation of the positive-feedback ampliﬁer
module (Figure 3B), bypassing device inactivation by sequestration
of the inﬂammatory signals in the immediate vicinity of the implant.
The production of therapeutic proteins with this device can be termi-
nated by the administration of a clinically licensed chemical mediator
Dox. Dox, acting via a repressor module, resets the therapeutic device
into the standby state as demonstrated in vitro (Figures 2C and 6A)
and in vivo (Figures 6B–6D). At the same time, the integrated
OFF-switch does not prevent the recurrent system activation as
shown in vitro (Figure 6A) and in vivo (Figure 6E).
The designed synthetic strategies against inﬂammation have already
been reported and included orally administered L. lactis secreting
IL-106 or anti-TNF-a nanobody7 and adenoviral IL-10 gene ther-
apy,50 which constitutively produce anti-inﬂammatory proteins.
These approaches demonstrated efﬁcacy in the murine colitis models.
The production capacity of the anti-inﬂammatory device, which was
activated autonomously upon encountering inﬂammatory signals,
was similar to these studies. As an example, we demonstrated the
in vivo efﬁcacy of the microencapsulated anti-inﬂammatory device
in a DSS-induced acute murine colitis model evaluated by several
physiological parameters (Figure 7).
From an engineering perspective, the anti-inﬂammatory device in the
present study can be considered a gene regulatory circuit, in which the
active, therapeutic protein-producing state is triggered by an inﬂam-
matory signal and the OFF signal is provided by an external chemical
signal. This setup allows for a rapid autonomous activation and the
external control of the reset (e.g., when a physician decides that the
therapeutic production of anti-inﬂammatory proteins is no longer
required).
Recently, E. coli was engineered to detect and record the presence of
anhydrotetracycline in the mammalian gut, serving as a living diag-
nostic device.51 Detection of in vivo anti-inﬂammatory device activa-
tion (Figures 4E and 4F), representing an inﬂammatory episode,
could serve as a diagnostic reporter of an ongoing inﬂammatory pro-114 Molecular Therapy Vol. 25 No 1 January 2017cess or as a log of past inﬂammatory events, without having to
frequently sample the body ﬂuids of an organism.
The modular design of the device enables adaptation of a combina-
tion of effector proteins for the particular pathology and for an
optimal effect. Changing the sensor module allows alternative endog-
enous signals to be detected. The latter ability of the device was
demonstrated by introduction of the STAT3 responsive element,
which enabled IL-6 detection (Figure S4E). Combining two or more
input signals by an AND or similar logic could increase the speciﬁcity
of the response to different combinations of inﬂammatory mediators.
As this type of device would be used for patients diagnosed with
chronic inﬂammatory diseases, we speculate that the activation of
the device mediated by the NF-kB signal, activated also by other stim-
uli, such as bacterial or viral infection, should not cause a problem as
also infection-triggered inﬂammation can aggravate or even initiate
the disease.52–54 Furthermore, the ability to switch off the production
of anti-inﬂammatory therapeutics by applying a chemical signal
would allow the anti-inﬂammatory action to be bypassed, if required.
Although the capacity of the system decreased with time due to the
transient nature of the system, the device was still active also 6 days
after transfection in vitro; however, the productivity decreased at later
time points (Figure S7A). The underlying cause is probably a well-
documented phenomena of the intracellular plasmid degradation,
spontaneous loss, and dilution during cell divisions in transiently
transfected cells.55,56 We have demonstrated that the sensor and the
ampliﬁer constructs were present and activated in the same cell
48 hr after the transfection (Figure S3C). However, as expected, the
plasmid copy number per cell dropped within 5 days after transfec-
tion, but nevertheless, the ampliﬁer construct, which was introduced
at the lowest amounts, and the inducible OFF-switch representing a
safety mechanism, were still present at that time (Figure S7C). Impor-
tantly, the initial amounts of the inducible OFF-switch were much
higher than the amounts of the sensor and ampliﬁer, which are the
drivers of the device activation, ensuring that the safety switch is func-
tional for the duration of the device activity.
Although the reliability and robustness of the anti-inﬂammatory de-
vice were demonstrated in vitro and in vivo, it should be noted that, in
this conﬁguration, the device is a prototype that needs further reﬁne-
ments for clinical applications in human therapy. In particular, long-
term stable cell lines would need to be established by genome integra-
tion of the device, either using autologous or validated safe cell lines.
Particularly for the translation of the system from mice to a human
setting, the capacity to produce anti-inﬂammatory proteins and phar-
macodynamics analysis of the local concentration in the affected or-
gans will have to be taken into account for therapeutic applications.
The results indicated that the production levels of the anti-inﬂamma-
tory effectors were sufﬁcient to suppress inﬂammatory reactions in
mice (Figure 7) and that the engineered microencapsulated cells re-
mained viable in the in vitro culture (Figure S7D) and, more impor-
tantly, in the peritoneal cavity of mice (Figure S7E).
www.moleculartherapy.orgAlginate microencapsulation has already been tested in clinical
trials,57,58 for example, microencapsulated human islets transplanted
into a type 1 diabetic patient aided insulin independence for
9 months.59 Besides alginate microencapsulation, there are alternative
cell implantation technologies, such as biocompatible hollow ﬁbers,
which may enable an easy removal of the implanted device.60
Advancing safety and efﬁcacy of cell implantation technologies may
foster the translation of the designed synthetic biology-inspired pros-
thetic devices into the clinic.
In conclusion, the concept of an autonomous anti-inﬂammatory
device may provide an alternative to anti-inﬂammatory therapy and
the emerging ﬁeld of synthetic immunology61 may signiﬁcantly
contribute to the development of novel therapeutic solutions for
important medical problems.MATERIALS AND METHODS
Plasmid Construction
The genetic constructs used and designed in this study are listed and
explained in detail (including their architecture, construction
methods, and annotated sequences of relevant elements) in Table
S1. Key plasmids include the following: the sensor construct
pAS60, encoding the TRE-PNF-kB2-PMIN-driven GV16-myc expres-
sion unit (TRE-PNF-kB2-PMIN-GV16-myc); the ampliﬁer construct
pAS62, encoding the TRE-UAS-PMIN-driven GV16-myc expres-
sion unit (TRE-UAS-PMIN-GV16-myc); the double effector
construct pAS134, encoding the TRE-UAS-PMIN-driven anti-
hTNF-a antibody-mIL-10-myc double effector expression unit
(TRE-UAS-PMIN-anti-hTNF-a Ab-mIL-10; DE2); the positive-feed-
back thresholder construct pAS67, encoding the constitutive HSV-
TK promoter-driven Gal4-myc expression unit (PHSV-TK-G-myc);
the inducible OFF-switch construct pAS58, encoding constitutive
CMV-promoter-driven rtTR-NLS-KRAB expression (PCMV-rtTR-
NLS-KRAB); the luciferase reporter construct pAS51, encoding the
TRE-UAS-PMIN-driven luciferase expression unit (TRE-UAS-PMIN-
Luc); and the SEAP reporter construct pAS72, encoding the TRE-
UAS-PMIN-driven SEAP expression unit (TRE-UAS-PMIN-SEAP).Cell Culture and Transfection
The HEK293T cell line (American Type Culture Collection) was
cultured in DMEM+GlutaMAX-I medium (Invitrogen) (supple-
mented with 10% fetal bovine serum) (BioWhittaker) at 37C in a
5% CO2 humidiﬁed atmosphere. At 50%–70% conﬂuence, cells
were transfected with a mixture of DNA and JetPEI (Polyplus-trans-
fection) according to the manufacturer’s instructions.Inducer Molecules
For in vitro experiments, doxycycline hyclate (Sigma-Aldrich; D9891)
was dissolved in MQ at a concentration of 0.1 mg/mL, sterile ﬁltered,
and used at a ﬁnal concentration of 1 mg/mL. For in vivo experiments,
doxycycline was dissolved in PBS at 5 mg/mL (pH 7.3), sterile ﬁltered,
and used at a ﬁnal concentration of 20 mg/kg. Human IL-1b and hu-
man TNF-a (R&D Systems) were used at a ﬁnal concentration of1 ng/mL in the in vitro experiments and at 250 ng/mouse in the in vivo
experiments, unless stated otherwise.
Transfection and Dual Luciferase Assay
The HEK293T cells (2  104 cells per well) were seeded into CoStar
White 96-well plates (Corning). At a conﬂuence of 50%–70%, cells
were transfected with a mixture of DNA and JetPEI (Polyplus-trans-
fection) according to the manufacturer’s instructions. Detailed infor-
mation about the transfected plasmids and their amount in a speciﬁc
experiment are provided in Table S2. After 24 hr, cells were activated
as stated in the speciﬁc experiment. After 24 or 48 hr, cells were har-
vested and lysed with 30 mL of 1 passive lysis buffer (Promega).
Fireﬂy luciferase and Renilla luciferase expression were measured
using a dual luciferase assay (Promega) and an Orion II microplate
reader (Berthold Technologies). The relative luciferase activity was
calculated by normalizing each sample’s ﬁreﬂy luciferase activity to
the constitutive Renilla luciferase activity determined in the same
sample.
Stimulation with Human Serum
Human serumwas collected from four healthy individuals and from a
patient with a sJIA. Pooled serum samples (n = 4) from healthy indi-
viduals were tested along with the serum from a patient in a 1:1 dilu-
tion for the anti-inﬂammatory device activation according to the
protocol described in Transfection and Dual Luciferase Assay (for in-
formation about the transfected plasmids, see Table S2). Written
informed consent for obtaining blood samples from healthy controls
and from a patient was obtained. Principles of the Declaration of
Helsinki were followed, and the Slovenian National Medical Ethics
Committee approved the study (decree number 29_2_13).
SEAP Detection
Human placental SEAP levels were determined in cell culture super-
natants using a QUANTI-Blue assay (InvivoGen) according to the
manufacturer’s instructions. Brieﬂy, 30 mL of supernatant was added
to 200 mL of pre-warmed (37C), sterile-ﬁltered QUANTI-Blue re-
agent solution. After 15 min, the absorbance was measured at
630 nm using a Synergy Mx automated microplate reader (BioTec).
The SEAP levels in blood samples and peritoneal lavage ﬂuid of the
mice were quantiﬁed using a chemiluminescence-based assay (Great
EscAPe SEAPChemiluminescence Kit 2.0; Clontech) according to the
manufacturer’s instructions, with a few adaptations. Brieﬂy, 5 mL of
serum or 15 mL of peritoneal lavage ﬂuid was mixed with 95 or
85 mL of a 1 dilution buffer, respectively, and incubated for
30 min at 65C to heat inactivate endogenous phosphatases. After
cooling to room temperature (22C), 100 mL of substrate solution
was added. After 10 min, the samples were centrifuged (2 min,
20,000  g), and 100 mL of the supernatant was transferred to CoStar
White 96-well plates (Corning). Thirty minutes after the addition of
the substrate solution, the luminescence was measured with an Orion
II microplate reader (Berthold Technologies). As an internal control,
the activity of the constitutive secretory Renilla luciferase SR-Luc
(pFLAG-CMV3-R-Luc; pAS75, Table S1) was measured in 50 mL of
the same sample.Molecular Therapy Vol. 25 No 1 January 2017 115
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The cells were microencapsulated in 400-mm alginate-PLL-alginate
microcapsules (approximately 200 cells/microcapsule) using the
Encapsulator Biotech (Büchi), according to the manufacturer’s proto-
col and as previously described.62 The following settings were applied:
a 200 mM single nozzle, a 20-mL syringe with a ﬂow of 19 mL/min,
a vibration frequency of 1,200 Hz, an electrostatic dispersion of
1,300 V, and a stirrer speed of 200 rpm. We used 1.4% ultrapure algi-
nate (PRONOVA UP LVG; Novamatrix) and 0.04% poly-L-lysine
hydrobromide (molecular weight [mol wt], 15.000-30.000 PLL;
Sigma-Aldrich; P7890). The microencapsulated cells were used for
in vitro or in vivo experiments.
Confocal Fluorescence Microscopy
To directly observe the system’s performance in vitro, HEK293T cells
were seeded onto eight-well microscopic chambers (Ibidi) at a density
of 5  104 cells per well. Cells were transfected with the constructs
pAS97 (to observe the sensor’s activity) and/or pAS98 (to observe
the ampliﬁer’s activity), pAS72, pAS67, pAS58, pAS75, and
pmCherry-C1 (Table S1). Twenty-four hours after transfection, the
system was stimulated with human IL-1b (R&D Systems) at a ﬁnal
concentration of 1 ng/mL. Four hours after stimulation, the medium
was removed and the cells were washed three times using fresh me-
dium to remove input signal. After 24 hr, the responsiveness of the
system was visualized, and microscopic images were acquired using
a Leica TCS SP5 inverted laser-scanning microscope on a Leica
DMI 6000 CS module equipped with a HCX PL Fluotar L (20;
numerical aperture, 0.4) (Leica Microsystems).
Quantification and Biological Activity of Anti-inflammatory
Proteins
Supernatants from cell cultures or in vivo samples (the preparation
of the serum and peritoneal lavage ﬂuid was as described in Animal
Models) were collected, and protein levels were measured with a
sandwich ELISA (eBioscience). hIL-1RA was detected with a hu-
man IL-1RA Platinum ELISA (eBioscience; BMS2080), anti-
hTNF-a antibody was detected with a human IgG1 Platinum
ELISA (eBioscience; BMS2092TWO), and mouse IL-10 was de-
tected with a mouse IL-10 ELISA Ready-SET-Go! (2nd Generation)
(eBioscience; 88-7105-22). The biological activity of the hIL-1RA
and anti-hTNF-a antibody was determined by competitive inhibi-
tion of hIL-1b and hTNF-a signaling through the NF-kB promoter.
First, hIL-1RA and anti-hTNF-a antibody were produced in
supernatants of HEK293T cells, transfected with constitutive pro-
moter-driven expression form pAS35 and pAS114 (Table S1),
respectively. We transfected the reporter cell line HEK293T with
pAS40 and phRL-TK (Table S1) to observe NF-kB-driven luciferase
activity. The cells were stimulated with 20 ng/mL hIL-1b or
hTNF-a for 24 hr, to which we added (simultaneously or with
30-min preincubation) the titrated supernatant, containing anti-in-
ﬂammatory proteins to observe the molar ratio-dependent decrease
in luciferase activity. Recombinant human IL-1RA (Sigma-Aldrich;
SRP3084) and anti-hTNF-a-hIgG1 (InvivoGen; htnfa-mab1) were
used as controls.116 Molecular Therapy Vol. 25 No 1 January 2017Animal Models
For the all in vivo experiments, 8- to 10-week-old C57BL/
6JOlaHsd mice of mixed sexes (evenly distributed between the
groups) were used. The numbers of mice are stated in the ﬁgure
captions.
The microcapsules were produced as described in Microencapsula-
tion. A 1:1 suspension of microcapsules with MOPS buffer (10 mM
MOPS, 0.85% NaCl) was prepared and 700 mL were injected
i.p. into the mice using a 20G needle (10,000 microcapsules per
mouse, 200 cells per microcapsule), as described previously.62
To determine the responsiveness of the synthetic anti-inﬂammatory
device to an inﬂammatory signal in vivo (for information on the
transfected plasmids, see Table S2), we injected mice i.p. with
300 ng of hIL-1b per mouse or 250 ng of hTNF-a per mouse 1 and
24 hr after implantation. Serum was collected using Multivette 600
(Sarstedt; 3,000 rpm, 30 min) 24 and 48 hr later, and peritoneal lavage
ﬂuid was collected after 48 hr (5 mL of PBS). We tested the peritoneal
lavage ﬂuid for system activation ex vivo.
To demonstrate activation of the anti-inﬂammatory device by endog-
enous mouse cytokines, we performed CLP model following the
described method.32,63 In Figure 4A, we collected peritoneal lavage
ﬂuid 24 hr after CLP procedure; in Figure 4F, we performed CLP
1 day before, and in Figure 5D, 3 hr before microcapsules
implantation.
For the in vivo restraint (Figure 6B) (see Table S2 for information on
the transfected plasmids used in the study), the mice were ﬁrst in-
jected i.p. with a combination of 300 ng of hIL-1b and 250 ng of
hTNF-a per mouse 1 hr after implantation. After 1 hr and every
24 hr, 20 mg/kg of Dox was injected intravenously (i.v.).
For the in vivo shut down (Figures 6C and 6D) (see Table S2 for in-
formation on the transfected plasmids used in the study), the mice
were ﬁrst injected i.p. with a combination of 300 ng of hIL-1b and
250 ng of hTNF-a per mouse 1 hr after implantation. After 24 hr (Fig-
ures 6C and 6D) and in addition after 72 hr (Figure 6C), 20 mg/kg of
Dox was injected i.v. In the case of Figure 6C, at 72-hr time point, the
mice in ON and OFF groups were injected i.p. also with a combina-
tion of 300 ng of hIL-1b and 250 ng of hTNF-a per mouse simulta-
neously with Dox injection. Serum was collected, and anti-hTNF-a
and mIL-10 concentrations were proﬁled. Control values were sub-
tracted from the ON and OFF state, and results were represented as
a percentage of a fully activated system (raw data are presented in Fig-
ures S6C and S6D).
For the in vivo reactivation (Figure 6E) (see Table S2 for information
on the transfected plasmids used in the study), 20 mg/kg of Dox was
injected i.v. into mice 1 hr after implantation. After 72 hr, the system
was activated by a single application of 300 ng of hIL-1b and 250 ng of
hTNF-a per mouse, and peritoneal lavage ﬂuid was collected 120 hr
after implantation.
www.moleculartherapy.orgTo produce therapeutic anti-inﬂammatory proteins in vivo, the mice
were injected i.p. with a combination of 500 ng of hIL-1b and 250 ng
of hTNF-a per mouse 1 hr after implantation. After 48 hr, serum and
peritoneal lavage ﬂuid were collected.
The application of the anti-inﬂammatory device in vivo was then
demonstrated in an acute murine colitis model.64 Themice were given
either water or 2% DSS (TdB Consultancy, DB001-31) for 8 days as
previously described, and on the ﬁfth day (Figure 7, except for D) of
this time-course experimental model, the microcapsules containing
anti-inﬂammatory device-engineered cells were implanted i.p. The
control groups without microcapsules received 700 mL of MOPS
buffer. One hour after implantation and then daily, the mice were
injected i.p. with a combination of 300 ng of hIL-1b and 250 ng of
hTNF-a per mouse. Weight, stool blood, and stool consistency were
monitored daily. Disease activity index (DAI) was determined by
combining the stool blood and stool consistency scores. Each score
was determined as follows: stool blood, 0–2 (0, no blood; 1, hemoocult
bleeding; 2, gross bleeding); and stool consistency, 0–2 (0, normal
stool; 1, soft stool; 2, diarrhea). Upon the sacriﬁce of the mice, the
colon length was measured from the body of the caecum to the distal
part of the rectum. Histological samples of the sacriﬁced mice were
ﬁxated overnight in 10% neutral buffered formalin (Sigma-Aldrich;
HT501128) and then embedded in parafﬁn (Leica; Paraplast;
39601006). The parafﬁn blocks were cut 7 mm thick with a rotation
microtome RM 2245 (Leica; 1492245UL01) and stained with hema-
toxylin and eosin (Sigma-Aldrich; MHS32; HT110332). The histolog-
ical score was determined as previously described: formation of ulcus,
0–4; epithelium morphology, 0–4; immune cell inﬁltration, 0–4; and
lymph follicles, 0–4.65Alternatively, themicrocapsuleswere implanted
on the third day after DSS exposure (Figure 7D). In this case, the con-
trol group comprised full anti-inﬂammatory system that was initially
activated by injecting the mice with a combination of 300 ng of hIL-
1b and 250 ng of hTNF-a per mouse, and the activation of the circuit
was simultaneously restrained by a daily i.v. Dox injection (20 mg/kg).
All of the animal experiments were performed according to the direc-
tives of the EU 2010/63, approved by the Ministry of Agriculture,
Forestry, and Foods, Republic of Slovenia (no. U34401-55/2013/6).
Mathematical Model and Simulations
The mathematical model and simulations are explained in detail in
Supplemental Mathematical Model. Brieﬂy, the mathematical model
was generated using CellDesigner 4.4 software23 by ﬁrst constructing
a state transition diagram and describing the transitions with ODEs
according to mass action kinetics. The initial quantities of genetic
constructs were approximated by estimating the efﬁciency of tran-
sient transfection. The input signal for the modeled genetic device
was the NF-kB particle number, and the output signal was the
effector protein particle number. The simulations were run with the
CellDesigner 4.4 software using an integrated SBML ODE Solver.66
Statistics
Representative experiments are shown. All values are represented as
the mean ± SD, except for in Figures 7C and 7F, where the mean ±SEM is shown. The data were analyzed with two-tailed Student’s
t test assuming unequal variances, except in Figure 7F, where a
Mann-Whitney U test was used. p values are shown for each compar-
ison of interest.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Materials and
Methods, seven ﬁgures, ﬁve tables, and can be found with this article
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